Cardiovascular Magnetic Resonance In Autoimmune Rheumatic Diseases: A Clinical Consensus Document By The European Association Of Cardiovascular Imaging

dc.contributor.authorMavrogeni, S.
dc.contributor.authorPepe, A.
dc.contributor.authorNijveldt, R.
dc.contributor.authorNtusi, N.
dc.contributor.authorSierra-Galan, L. M.
dc.contributor.authorBratis, K.
dc.contributor.authorWei, J.
dc.contributor.authorMukherjee, M.
dc.contributor.authorMarkousis-Mavrogenis, G.
dc.contributor.authorGargani, L.
dc.contributor.authorSade, L. E.
dc.contributor.authorAjmone-Marsan, N.
dc.contributor.authorSeferovic, P.
dc.contributor.authorDonal, E.
dc.contributor.authorNurmohamed, M.
dc.contributor.authorCerinic, M. Matucci
dc.contributor.authorSfikakis, P.
dc.contributor.authorKitas, G.
dc.contributor.authorSchwitter, J.
dc.contributor.authorLima, J. A. C.
dc.contributor.pubmedID35808990en_US
dc.date.accessioned2022-12-20T09:06:09Z
dc.date.available2022-12-20T09:06:09Z
dc.date.issued2022
dc.description.abstractAutoimmune rheumatic diseases (ARDs) involve multiple organs including the heart and vasculature. Despite novel treatments, patients with ARDs still experience a reduced life expectancy, partly caused by the higher prevalence of cardiovascular disease (CVD). This includes CV inflammation, rhythm disturbances, perfusion abnormalities (ischaemia/infarction), dysregulation of vasoreactivity, myocardial fibrosis, coagulation abnormalities, pulmonary hypertension, valvular disease, and side-effects of immunomodulatory therapy. Currently, the evaluation of CV involvement in patients with ARDs is based on the assessment of cardiac symptoms, coupled with electrocardiography, blood testing, and echocardiography. However, CVD may not become overt until late in the course of the disease, thus potentially limiting the therapeutic window for intervention. More recently, cardiovascular magnetic resonance (CMR) has allowed for the early identification of pathophysiologic structural/functional alterations that take place before the onset of clinically overt CVD. CMR allows for detailed evaluation of biventricular function together with tissue characterization of vessels/myocardium in the same examination, yielding a reliable assessment of disease activity that might not be mirrored by blood biomarkers and other imaging modalities. Therefore, CMR provides diagnostic information that enables timely clinical decision-making and facilitates the tailoring of treatment to individual patients. Here we review the role of CMR in the early and accurate diagnosis of CVD in patients with ARDs compared with other non-invasive imaging modalities. Furthermore, we present a consensus-based decision algorithm for when a CMR study could be considered in patients with ARDs, together with a standardized study protocol. Lastly, we discuss the clinical implications of findings from a CMR examination.en_US
dc.identifier.endpageE322en_US
dc.identifier.issn2047-2404en_US
dc.identifier.issue9en_US
dc.identifier.scopus2-s2.0-85136161040en_US
dc.identifier.startpageE308en_US
dc.identifier.urihttps://watermark.silverchair.com/jeac134.pdf?token=AQECAHi208BE49Ooan9kkhW_Ercy7Dm3ZL_9Cf3qfKAc485ysgAAAuYwggLiBgkqhkiG9w0BBwagggLTMIICzwIBADCCAsgGCSqGSIb3DQEHATAeBglghkgBZQMEAS4wEQQMba90LpjE8XcN3iRWAgEQgIICmZ488BEuL_KYx-2zeY6EU5xy2gk4hxhXiFfxgQblytkm57TPMdivk8_bEoybKnnENjjv3LnXSQ2hnIs1H_Qk8F9LNXbN-Z3Zzb19pDloebcj4X3zU3TYxKzmXoGL-3cjrSdn0znPdbPMy2IxL5j_-sfzpESEywZppWE_Pyd6GdKdBriHuAgQmEV0uFXdFwcCV5eUkKGHz0jgVlT9Y1-h_AiLabQXY0g4WFtUo0RC_hM-nTh71ue_B48C4eO4Sk2_OnjyysuwOmDRyhH27q9FBggeRnb05KfLYWIC8tzuWWcNsVcayVvunjYKEQQH3k40ATNgMntfCF1DBgu3qxwdlo6GQp0Rgq4oE4vSZaoFI04UJ7IuD4tURCpOLAV1WZjCyhxYcIQck0G6kEqwOiyo4OfFT1l1vE5-bCWqOq8rVXPdSuy5CKvNIphEjF2Yg3BDnPjMFUh00JrfhacMnxru_3LgQsVWk67U3nFOhQAsn20ElDPNYViqObDp0o-lzc_pszwACmdKh_MDtxmjTCOQZ_khsln6WiGkXjiuvKXK8_olj1s1MIfLSRTmO-TkywI9bCxfhkThDSIzDf8zLXwWnYd-_5Q90cbuHpfx9UzWG2p_R7Kf4FxsMgGRGl-mnw9XZl_BGN7I8qrIVHHyajEkXHl_gcTQYW9TmjGIK-ZKiacNDsvs5Mde3PWE_WnP0hMBN_-6PS7CbjItqMAuJjVLSQQY1Pj1ZHRN3ZnJmGSntdTNGKBU3n36x7HfRGXSztkU2jpkhnu2pKyL9vHJzZKqYMQ0m6uz9Be0vdI1Q4UyWyQMEuhiiD3d4rXLfiUkrhAo1eiWN2oDoI-buN2UMJOfULuOu4I9WS-BN9-ZqFZd2ao1614a3ekarLEQ
dc.identifier.urihttp://hdl.handle.net/11727/8357
dc.identifier.volume23en_US
dc.identifier.wos000822385000001en_US
dc.language.isoengen_US
dc.relation.isversionof10.1093/ehjci/jeac134en_US
dc.relation.journalEUROPEAN HEART JOURNAL-CARDIOVASCULAR IMAGINGen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergien_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectechocardiographyen_US
dc.subjectcoronary artery diseaseen_US
dc.subjectinflammatory myocardial diseaseen_US
dc.subjectinflammatory vascular diseaseen_US
dc.subjectvalvular heart diseaseen_US
dc.subjectpulmonary hypertensionen_US
dc.subjectmyocardial fibrosisen_US
dc.subjectvessel fibrosisen_US
dc.titleCardiovascular Magnetic Resonance In Autoimmune Rheumatic Diseases: A Clinical Consensus Document By The European Association Of Cardiovascular Imagingen_US
dc.typearticleen_US

Files

Original bundle

Now showing 1 - 1 of 1
No Thumbnail Available
Name:
109.pdf
Size:
907.8 KB
Format:
Adobe Portable Document Format
Description:

License bundle

Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description: